RÉSUMÉ DIGEST
ACT 241 (SB 257) 2022 Regular Session Fred Mills
New law requires the La. Medicaid program to provide coverage for a continuous glucose
monitor for the treatment of an enrollee who has any type of diabetes with the use of insulin
more than two times daily or evidence of level 2 or level 3 hypoglycemia or who has
glycogen storage disease type 1a.
New law requires an enrollee who receives coverage for a continuous glucose monitor to
attend regular follow-up visits with a healthcare provider at a minimum of every six months
to assess the ongoing benefit of the enrollee's use of a continuous glucose monitor.
New law requires the La. Dept. of Health to implement the coverage requirement of new law
using the most cost-effective solution available to the department.
Effective August 1, 2022.
(Adds R.S. 46:450.8)